AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10071523
Drug: NADH (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NADH (10 mg)
Trial: 7174213
Drug: Hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital treatment with short-wave diathermy and daily exercises with graduated weights
Trial: 15085090
Drug: Ethanol influx
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol influx (40 g bolus infusion)
Trial: 10436958
Drug: Xuezhikang (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (4 capsules/day, 1.2 g/day for 8 weeks)
Trial: 10436958
Drug: Simvastatin (Zocor,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (Zocor, 10 mg/day for 8 weeks)
Trial: 7635024
Drug: Routine iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine iron supplements during pregnancy
Trial: 7635024
Drug: No iron
RxNorm normalized name: No Iron Multivitamin with Minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No iron supplements during pregnancy
Trial: 27856432
Drug: Sarilumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab (200 mg every 2 weeks)
Trial: 26473625
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg every 2 weeks)
Trial: 25604769
Drug: ω3 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω3 plus low‐dose aspirin for 6 months
Trial: 19332209
Drug: Adenosine or
RxNorm normalized name: adenosine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine or regadenoson administration
Trial: 16968790
Drug: Systemic nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic nonselective COX inhibition (100 mg indomethacin)
Trial: 16968790
Drug: Selective COX-2
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective COX-2 blockade (200 mg celecoxib)
Trial: 16968790
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (8 mg/min.dl)
Trial: 16968790
Drug: L-NMMA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (100 microg/min.dl)
Trial: 15517116
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 to 150 mg daily
Trial: 11393553
Drug: 4 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 days intravenous insulin infusion annually followed by b.i.d. low doses of subcutaneous ultralente insulin
Trial: 2885639
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose polymer solution (302 mOsm/kg)
Trial: 2885639
Drug: 1.36% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.36% glucose solution (332 mOsm/kg)
Trial: 2885639
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose polymer solution
Trial: 26791478
Drug: Kundalini yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kundalini yoga programme (15min twice-daily for 12 weeks)
Trial: 22620695
Drug: Spinosad at
RxNorm normalized name: Spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinosad at the manufacturer's recommended dose
Trial: 17126403
Drug: Dorzolamide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide treatment
Trial: 11996471
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin/etoposide (PE) followed by hyperfractionated accelerated radiotherapy (HF-RTx; 1.5 Gy bid up to a total dose of 45 Gy in 3 weeks) concurrent with one cycle of PE, and a small volume boost of 20 Gy (qd) for a total of 65 Gy to the primary.
Trial: 2676249
Drug: Normal sodium
RxNorm normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal sodium intake group (44 subjects receiving less than 80 mmol sodium daily in the diet plus 80 mmol of sodium supplement as eight slow release sodium chloride tablets daily)
Trial: 2676249
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium intake group (44 subjects receiving less than 80 mmol sodium daily in the diet plus eight slow release sodium chloride placebo tablets daily)
Trial: 24357
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg lorazepam via deep intramuscular injection
Trial: 24357
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg lorazepam via deep intramuscular injection
Trial: 24357
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg lorazepam via intravenous injection
Trial: 24357
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg lorazepam via intravenous injection
Trial: 24357
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg and 4 mg lorazepam via any route
Trial: 30335625
Drug: 0.050 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.050 μg · kg(‐1) · min(‐1) norepinephrine infusion
Trial: 30335625
Drug: 0.075 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 μg · kg(‐1) · min(‐1) norepinephrine infusion
Trial: 30335625
Drug: 0.025 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 μg · kg(‐1) · min(‐1) norepinephrine infusion (control)
Trial: 25754162
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dose of oral isotretinoin
Trial: 25754162
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dose of oral isotretinoin
Trial: 25754162
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens of oral isotretinoin
Trial: 21546612
Drug: Tadalafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (5 mg once daily for 90 days)
Trial: 21546612
Drug: Endothelial antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelial antioxidant compound (EAC) administration after tadalafil discontinuation for 6 months
Trial: 21546612
Drug: No other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No other treatment during follow-up after tadalafil cessation
Trial: 15066454
Drug: Daily 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 150 IU recombinant hFSH
Trial: 7739942
Drug: Generic slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic slow-release theophylline tablet
Trial: 21692673
Drug: Antiviral drug
RxNorm normalized name: antiviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drug therapy
Trial: 31821732
Drug: Olaratumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaratumab (15 mg/kg) + Doxorubicin (75 mg/m2)
Trial: 31821732
Drug: Olaratumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaratumab (20 mg/kg) + Doxorubicin (75 mg/m2)
Trial: 25962070
Drug: Sparkling white
RxNorm normalized name: Sparkling white wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparkling white wine (340 mL; 30 g alcohol) in unpleasant ambiance
Trial: 25962070
Drug: Sparkling white
RxNorm normalized name: Sparkling white wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparkling white wine (340 mL; 30 g alcohol) in pleasant ambiance
Trial: 25962070
Drug: Alcohol-free sparkling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-free sparkling white wine (340 mL; <2 g alcohol) in unpleasant ambiance
Trial: 25962070
Drug: Alcohol-free sparkling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-free sparkling white wine (340 mL; <2 g alcohol) in pleasant ambiance
Trial: 21520432
Drug: High-frequency oscillatory
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency oscillatory ventilation (HFOV) plus inhaled nitric oxide (iNO)
Trial: 21520432
Drug: Pressure-controlled assist/control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure-controlled assist/control ventilation (PCACV) plus inhaled nitric oxide (iNO)
Trial: 18579510
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg mifepristone every other day for 3 months
Trial: 18261860
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment for alcohol dependence
Trial: 11480805
Drug: Target-absent photo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target-absent photo lineup administered by interviewers who were misinformed about the thief's position.
Trial: 29638147
Drug: 20 mEq
RxNorm normalized name: potassium chloride 20 MEQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mEq magnesium L-lactate dihydrate under fasting conditions
Trial: 29638147
Drug: 20 mEq
RxNorm normalized name: potassium chloride 20 MEQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mEq magnesium L-lactate dihydrate under fed conditions
Trial: 29638147
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 20 mEq magnesium sulfate
Trial: 27533046
Drug: Pre-existing anti-Vi
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-existing anti-Vi antibody
Trial: 11781912
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg droperidol intramuscularly
Trial: 11781912
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg meperidine intramuscularly
Trial: 9831973
Drug: Fenofibrate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (300 mg daily)
Trial: 9831973
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg daily)
Trial: 8208098
Drug: Thyropol (thyroid-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyropol (thyroid-releasing hormone film)
Trial: 2734721
Drug: Ornidazole administered
RxNorm normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole administered by one daily IV infusion at 20 mg/kg
Trial: 2734721
Drug: Ornidazole administered
RxNorm normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole administered by two daily IV infusions at 20 mg/kg
Trial: 31948990
Drug: TKR plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKR plus 12 weeks of supervised non-surgical treatment (exercise, education, diet, insoles and pain medication)
Trial: 29723634
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment alone
Trial: 31948990
Drug: TKR plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKR plus non-surgical treatment
Trial: 30900905
Drug: Buccal dissolution
RxNorm normalized name: Witch Hazel 30 mg in 30 mL TOPICAL PATCH [LEADERS INSOLUTION COCONUT LIFTING RECOVERY MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal dissolution test with polymer coatings (Surelease:Opadry at 8, 12, and 16% weight gain; Opadry EC at 4, 6, and 8% weight gain; Kollicoat Smartseal 100P at 10% weight gain)
Trial: 12460133
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control (DTC)
Trial: 21554549
Drug: udenafil 100
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: udenafil 100 mg
Trial: 21083516
Drug: Enoxaparin T
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin T (40 mg daily for 7 days)
Trial: 21083516
Drug: Enoxaparin R
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin R (40 mg daily for 7 days)
Trial: 11205424
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections (two injections separated by 15 min)
Trial: 9272133
Drug: CHOP (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP (standard therapy)
Trial: 8511091
Drug: HDCV 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDCV 2 injections (days 0 and 28)
Trial: 8511091
Drug: HDCV 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDCV 3 injections (days 0, 7, and 28)
Trial: 8511091
Drug: PVRV 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV 2 injections (days 0 and 28)
Trial: 8511091
Drug: PVRV 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV 3 injections (days 0, 7, and 28)
Trial: 8511091
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose at 1 year
Trial: 3493614
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg X kg‐1
Trial: 3493614
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg X kg‐1
Trial: 16377282
Drug: Morning intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning intake of atorvastatin
Trial: 16377282
Drug: Evening intake
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening intake of atorvastatin
Trial: 11314241
Drug: Mud bath
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud bath treatment (group A)
Trial: 11314241
Drug: Bath treatment
RxNorm normalized name: Aveeno Soothing Bath Treatment
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bath treatment alone (group B)
Trial: 30509675
Drug: Cefiderocol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefiderocol (2 g) administered intravenously three times daily for 7-14 days
Trial: 30509675
Drug: Imipenem-cilastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (1 g each) administered intravenously three times daily for 7-14 days
Trial: 30509675
Drug: Cefiderocol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefiderocol (2 g)
Trial: 30509675
Drug: Imipenem-cilastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (1 g each)
Trial: 28076940
Drug: Iso sorbide
RxNorm normalized name: iso-sulfan blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iso sorbide mononitrate (ISMN) 60 mg sustained release, self-administered vaginally every other day for five doses
Trial: 28076940
Drug: Pyridoxine 10
RxNorm normalized name: pyridoxine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine 10 mg (control)
Trial: 22257581
Drug: i.v. 1
RxNorm normalized name: Monistat I.V. 10 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. 1 mg tolvaptan
Trial: 22257581
Drug: oral 30
RxNorm normalized name: Aloral 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral 30 mg tolvaptan
Trial: 8514071
Drug: Midazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (mean dose in vasovagal group)
Trial: 8514071
Drug: Midazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (mean dose in control group)
Trial: 392375
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: decontaminated by nonabsorbable antibiotics in strict reverse isolation
Trial: 21461596
Drug: PGE(1) infusion
RxNorm normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE(1) infusion (2.5 ng/kg/min) for 4 weeks
Trial: 17198774
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg orally the day before and the morning of the operation, a bolus of 150 mg/kg of intravenous N-acetylcysteine before skin incision, followed by perfusion at 12.5 mg x kg(‐1) x h(‐1) over 24 hours; n = 50)
Trial: 14987884
Drug: Procalcitonin-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin-guided treatment (n=124)
Trial: 9764348
Drug: Heparin/Aspirin (H/A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin/Aspirin (H/A) not administered
Trial: 9764348
Drug: Heparin/Aspirin (H/A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin/Aspirin (H/A) with Intravenous Immunoglobulin G (IVIg)
Trial: 31611626
Drug: Intensive block-based
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive block-based chemotherapy (for slow responders with MRD > 0.1% on day 29)
Trial: 31611626
Drug: Intensive block-based
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive block-based chemotherapy
Trial: 31611626
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (both arms)
Trial: 31611626
Drug: Intensive block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive block therapy
Trial: 26108190
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide 400 mg/day for 8 days
Trial: 18374614
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 microg once daily for 28 days
Trial: 16869482
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment (discussion of problems)
Trial: 12590404
Drug: Fluvoxamine (100-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100-250 mg/day)
Trial: 11465584
Drug: Drug that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug that may increase the probability of survival by 20%
Trial: 30753091
Drug: Acetaminophen and
RxNorm normalized name: Acetaminophen and Aspirin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen and verbal behavior modification
Trial: 24226720
Drug: Other oral
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other oral nutritional supplements
Trial: 18032219
Drug: 1,000 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 g/d of B12 for participants with MMA > 271 nmol/L
Trial: 18032219
Drug: 0, 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0, 25, or 100 microg/d of B12 for participants with MMA <= 271 nmol/L
Trial: 11881102
Drug: telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 40 mg
Trial: 17996511
Drug: losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 100 mg
Trial: 8223837
Drug: Nizatidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (300 mg)
Trial: 8223837
Drug: Ranitidine (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (450 mg)
Trial: 19508966
Drug: CRx-102 (prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRx-102 (prednisolone 3 mg/day and dipyridamole 400 mg/day)
Trial: 16118673
Drug: IFN-alpha monotherapy
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha monotherapy (13 patients) at 9 million units 3 times weekly for 24 weeks
Trial: 16118673
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (14 patients) with IFN-alpha at 9 million units 3 times weekly for 24 weeks plus lamivudine 100 mg/day for 1 year
Trial: 7742706
Drug: O2‐O3 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O2‐O3 therapy
Trial: 7742706
Drug: HBO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBO therapy
Trial: 6825584
Drug: Prednisone (massive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (massive single dose and then alternating daily)
Trial: 6825584
Drug: Lymphokinetic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphokinetic drug (Venalot‐Depot)
Trial: 6112444
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of treatments
Trial: 30100106
Drug: 0.04 g
RxNorm normalized name: Glycerin 0.04 g in 1 g VAGINAL GEL [Inclear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 g hydrolyzed casein protein×kg ffm-1×2 h-1
Trial: 30100106
Drug: 0.10 g
RxNorm normalized name: RABBIT 0.10 g in 1 mL SUBCUTANEOUS INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 g hydrolyzed casein protein×kg ffm-1×2 h-1
Trial: 30100106
Drug: 0.30 g
RxNorm normalized name: Titanium Dioxide 0.30 g in 3.5 g TOPICAL POWDER [3CE TRIPLE SHADOW LEMME SEE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 g hydrolyzed casein protein×kg ffm-1×2 h-1
Trial: 24417600
Drug: Individual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Therapy (IT)
Trial: 29510651
Drug: No Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Therapy (NT)